The diagnosis of depression: current and emerging methods
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Depression is one of the leading causes of disability in adolescents and adults, particularly starting from age 15 years and older. Diagnosis of depression has traditionally been made based on clinical criteria, including patient current symptoms and history. This process is widely used but relies on subjective interpretation. To standardize both the data obtained and data interpretation, various interview-based instruments and noninterview methods exist for screening and testing for depression in various clinical settings. This article evaluates the technical basis for and clinical performance of these various instruments and methods to diagnosis depression in clinical settings. Traditional tools include physician-administered or patient self-administered interview tools that have reasonable clinical accuracy depending on the threshold score and may lead to a full diagnostic evaluation for high-risk patients. In addition, older laboratory methods such as the dexamethasone test have contributed to the diagnosis of depression over a long period. Newer diagnostic methods such as genomics, proteomics, and metabolomics are technically sophisticated and objective and are beginning to emerge in psychiatry. Although promising, further evaluation of these methods is needed to fully demonstrate their clinical value and accuracy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 5×
“Some studies show that antidepressant treatment may modulate neurogenesis-related markers such as brain-derived neurotrophic factor (BDNF) [20].”
InfluentialSen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Major depressive disorder in older adolescents
Lewinsohn, P. M., Rohde, P., & Seeley, J. R. (1998) · Clinical Psychology Review · doi:10.1016/s0272-7358(98)00010-5 · Cited by 1,078 · cited 1×
“Rates of depression among children and adolescents approach that in adults with reports indicating prevalences of 3% and 6% [3], respectively, and the lifetime prevalence of MDD among adolescents may be as high as 20% [4-6].”
LOWE, B. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00237-9 · Cited by 1,060
Is there an epidemic of child or adolescent depression?
Jane Costello, E., Erkanli, A., & Angold, A. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2006.01682.x · Cited by 983 · cited 1×
“Rates of depression among children and adolescents approach that in adults with reports indicating prevalences of 3% and 6% [3], respectively, and the lifetime prevalence of MDD among adolescents may be as high as 20% [4-6].”
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
Major Depression and Activation of The Inflammatory Response System
Maes, M. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_2 · Cited by 617 · cited 2×
“Severe depressive illness has been associated with elevations of cytokines or their soluble receptors, including interleukin (IL)-2, soluble IL-2 receptors (sIL-2R), IL-1b, IL-1 receptor antagonist (IL1Ra), IL-6, soluble IL-6 receptor (sIL-6R), and γ-interferon [26,30].”
Zhu, C.-B., Blakely, R. D., & Hewlett, W. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301029 · Cited by 549 · cited 1×
“Pathways such as the inflammatory, neurotrophic, metabolic, and hypothalamicpituitary-adrenal (HPA) axis express and respond to many regulatory biochemicals that include steroids, neuropeptides, cytokines, and neurotransmitters [26-28].”
The Dexamethasone Suppression Test for Diagnosis and Prognosis in Psychiatry: Commentary and Review
Arana, G. W. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790350067012 · Cited by 526
Effects of antidepressants on the production of cytokines
Kenis, G., & Maes, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003164 · Cited by 370 · cited 1×
“Components of several biological pathways undergo changes in various psychiatric conditions or in response to antipsychiatric therapy [24,25].”
A detailed examination of cytokine abnormalities in Major Depressive Disorder
Simon, N. M., McNamara, K., Chow, C. W., Maser, R. S., Papakostas, G. I., Pollack, M. H., Nierenberg, A. A., Fava, M., & Wong, K. K. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.06.004 · Cited by 286 · cited 1×
“Severe depressive illness has been associated with elevations of cytokines or their soluble receptors, including interleukin (IL)-2, soluble IL-2 receptors (sIL-2R), IL-1b, IL-1 receptor antagonist (IL1Ra), IL-6, soluble IL-6 receptor (sIL-6R), and γ-interferon [26,30].”
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.10.1253 · Cited by 262
Papakostas, G. I., Shelton, R. C., Kinrys, G., Henry, M. E., Bakow, B. R., Lipkin, S. H., Pi, B., Thurmond, L., & Bilello, J. A. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.166 · Cited by 180 · cited 1×
“One recently reported independent study evaluated this biomarker panel initially in 36 patients with MDD and 43 nondepressed subjects [40].”
Self-citation
Cited by
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102
Deep-Asymmetry: Asymmetry Matrix Image for Deep Learning Method in Pre-Screening Depression
Kang, M., Kwon, H., Park, J.-H., Kang, S., & Lee, Y. (2020) · Sensors · doi:10.3390/s20226526 · Cited by 71
MicroRNAs as critical biomarkers of major depressive disorder: a comprehensive perspective
Ortega, M. A., Alvarez-Mon, M. A., García-Montero, C., Fraile-Martinez, O., Lahera, G., Monserrat, J., Muñoz-Merida, L., Mora, F., Rodríguez-Jiménez, R., Fernandez-Rojo, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9111659 · Cited by 57
“In this sense, further approaches are being under research to facilitate the diagnosis, prognosis and prediction of MDD, including various laboratory markers, genomics, proteomics, metabolomics and multiple biological components [19,172,173].”
MethodExplainable depression symptom detection in social media
Bao, E., Pérez, A., & Parapar, J. (2024) · Health Information Science and Systems · doi:10.1007/s13755-024-00303-9 · Cited by 46
“The diagnosis of depressive disorder, which is the ultimately aim and scope of psychologists in this domain, relies on clinical factors such as the presence of clinical symptoms and their temporality [28].”
Background
Metadata
- Authors
- Smith, K. M., Renshaw, P. F., & Bilello, J.
- Venue
- Comprehensive Psychiatry
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 54
- Issue
- 1
- Pages
- 1-6
- ISSN
- 0010-440X (ISSN-L)
- OpenAlex
- W2080298947
- Cited by
- 120
- References
- 13
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.